Current status of the immunogenicity of enzyme replacement therapy in fabry disease
Abstract In patients with Fabry disease (FD), treatment with enzyme replacement therapy (ERT), may trigger the formation of anti-drug antibodies (ADAs). The consequences of this immune reaction range from the transient appearance of clinically insignificant ADAs to the generation of neutralizing ant...
Saved in:
| Main Authors: | Jorge F. Gómez-Cerezo, Julián Fernández-Martín, Miguel Ángel Barba-Romero, Rosario Sánchez-Martínez, Alvaro Hermida-Ameijeiras, Maria Camprodon-Gómez, Saida Ortolano, Mónica A. Lopez-Rodriguez |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Orphanet Journal of Rare Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13023-025-03705-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease
by: V. I. Ignatyeva, et al.
Published: (2019-01-01) -
NEUROLOGICAL MANIFESTATIONS OF FABRY DISEASE IN CHILDREN AND ADOLESCENTS
by: A. S. Kotov, et al.
Published: (2017-12-01) -
Current treatment status of fabry disease in South Korea: a longitudinal National health insurance service data-based study
by: DoHyeon Lee, et al.
Published: (2025-07-01) -
Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy
by: Uma Ramaswami, et al.
Published: (2025-06-01) -
Cardiomyopathy and kidney function in agalsidase beta‐treated female Fabry patients: a pre‐treatment vs. post‐treatment analysis
by: Christoph Wanner, et al.
Published: (2020-06-01)